CIBC Private Wealth Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

CIBC Private Wealth Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-260	Closed	-$22K	–	1815
2018 Q2	$22K	Sell	260 -419	-62%	-$30.7K	﹤0.01%	1380
2018 Q1	$42K	Buy	679 +404	+147%	+$24.3K	﹤0.01%	1202
2017 Q4	$16K	Buy	+275	New	+$17.3K	﹤0.01%	1451

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CIBC Private Wealth Group's ICPT Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2018, closing a stake of 260 shares — an estimated $22K sold.

CIBC Private Wealth Group first reported a position in ICPT in Q4 2017 and held it in 3 quarters. The position peaked at $42K in Q1 2018. 175 funds tracked by Wall St. Rank hold ICPT as of Q3 2018.

CIBC Private Wealth Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
CIBC Private Wealth Group sold 260 Intercept Pharmaceuticals, Inc. shares in Q3 2018, an estimated $22K.
CIBC Private Wealth Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
CIBC Private Wealth Group's Intercept Pharmaceuticals, Inc. position peaked at $42K in Q1 2018.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.